abstract |
The present invention relates to chemical compounds acting through GPR17 receptor for use in the treatment of diseases, in particular for use in chronic and/or acute neurodegenerative diseases, preferably Multiple Sclerosis, inflammatory diseases, pathologies involving the immune system, cardiovascular diseases, renal diseases. |